Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Goodwill & Intangibles (2021 - 2025)

Gain Therapeutics has reported Goodwill & Intangibles over the past 5 years, most recently at $114607.0 for Q3 2025.

  • Quarterly results put Goodwill & Intangibles at $114607.0 for Q3 2025, down 26.65% from a year ago — trailing twelve months through Sep 2025 was $114607.0 (down 26.65% YoY), and the annual figure for FY2024 was $134268.0, down 30.57%.
  • Goodwill & Intangibles for Q3 2025 was $114607.0 at Gain Therapeutics, down from $127857.0 in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for GANX hit a ceiling of $213967.0 in Q4 2022 and a floor of $114607.0 in Q3 2025.
  • Median Goodwill & Intangibles over the past 5 years was $189242.0 (2023), compared with a mean of $174364.5.
  • Biggest five-year swings in Goodwill & Intangibles: increased 5.61% in 2022 and later plummeted 30.57% in 2024.
  • Gain Therapeutics' Goodwill & Intangibles stood at $202609.0 in 2021, then increased by 5.61% to $213967.0 in 2022, then decreased by 9.62% to $193375.0 in 2023, then plummeted by 30.57% to $134268.0 in 2024, then dropped by 14.64% to $114607.0 in 2025.
  • The last three reported values for Goodwill & Intangibles were $114607.0 (Q3 2025), $127857.0 (Q2 2025), and $126291.0 (Q1 2025) per Business Quant data.